Report cover image

Emergency Hemostatic Agent Industry Research Report 2025

Publisher APO Research, Inc.
Published Sep 17, 2025
Length 139 Pages
SKU # APRC20462792

Description

Summary

According to APO Research, the global Emergency Hemostatic Agent market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Emergency Hemostatic Agent is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Emergency Hemostatic Agent is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Emergency Hemostatic Agent is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Emergency Hemostatic Agent include Advanced Medical Solutions, Anika Therapeutics, B Braun Melsungen, Baxter International, BioCer Entwicklungs, Biom’Up SAS, C. R. Bard, CryoLife and Equimedical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Emergency Hemostatic Agent, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Emergency Hemostatic Agent.

The report will help the Emergency Hemostatic Agent manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Emergency Hemostatic Agent market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Emergency Hemostatic Agent market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Emergency Hemostatic Agent Segment by Company

Advanced Medical Solutions
Anika Therapeutics
B Braun Melsungen
Baxter International
BioCer Entwicklungs
Biom’Up SAS
C. R. Bard
CryoLife
Equimedical
Ethicon
Gelita Medical
Integra LifeSciences
Marine Polymer Technologies
The Medicines Company
Vascular Solutions
Z-Medica
Pfizer
Emergency Hemostatic Agent Segment by Type

Gelation Sponge
Oxidized Regenerated Cellulose Based Hemostats
Others
Emergency Hemostatic Agent Segment by Application

Clnics
Hospitals
Surgical Centers
Others
Emergency Hemostatic Agent Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Emergency Hemostatic Agent market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Emergency Hemostatic Agent and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Emergency Hemostatic Agent.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Emergency Hemostatic Agent manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Emergency Hemostatic Agent by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Emergency Hemostatic Agent in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Table of Contents

139 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Emergency Hemostatic Agent Market Size (2020-2031)
2.2.2 Global Emergency Hemostatic Agent Sales (2020-2031)
2.2.3 Global Emergency Hemostatic Agent Market Average Price (2020-2031)
2.3 Emergency Hemostatic Agent by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Gelation Sponge
2.3.3 Oxidized Regenerated Cellulose Based Hemostats
2.3.4 Others
2.4 Emergency Hemostatic Agent by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Clnics
2.4.3 Hospitals
2.4.4 Surgical Centers
2.4.5 Others
3 Market Competitive Landscape by Manufacturers
3.1 Global Emergency Hemostatic Agent Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Emergency Hemostatic Agent Sales (K Units) of Manufacturers (2020-2025)
3.3 Global Emergency Hemostatic Agent Revenue of Manufacturers (2020-2025)
3.4 Global Emergency Hemostatic Agent Average Price by Manufacturers (2020-2025)
3.5 Global Emergency Hemostatic Agent Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Emergency Hemostatic Agent, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Emergency Hemostatic Agent, Product Type & Application
3.8 Global Manufacturers of Emergency Hemostatic Agent, Established Date
3.9 Global Emergency Hemostatic Agent Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Advanced Medical Solutions
4.1.1 Advanced Medical Solutions Company Information
4.1.2 Advanced Medical Solutions Business Overview
4.1.3 Advanced Medical Solutions Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Advanced Medical Solutions Emergency Hemostatic Agent Product Portfolio
4.1.5 Advanced Medical Solutions Recent Developments
4.2 Anika Therapeutics
4.2.1 Anika Therapeutics Company Information
4.2.2 Anika Therapeutics Business Overview
4.2.3 Anika Therapeutics Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Anika Therapeutics Emergency Hemostatic Agent Product Portfolio
4.2.5 Anika Therapeutics Recent Developments
4.3 B Braun Melsungen
4.3.1 B Braun Melsungen Company Information
4.3.2 B Braun Melsungen Business Overview
4.3.3 B Braun Melsungen Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2020-2025)
4.3.4 B Braun Melsungen Emergency Hemostatic Agent Product Portfolio
4.3.5 B Braun Melsungen Recent Developments
4.4 Baxter International
4.4.1 Baxter International Company Information
4.4.2 Baxter International Business Overview
4.4.3 Baxter International Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Baxter International Emergency Hemostatic Agent Product Portfolio
4.4.5 Baxter International Recent Developments
4.5 BioCer Entwicklungs
4.5.1 BioCer Entwicklungs Company Information
4.5.2 BioCer Entwicklungs Business Overview
4.5.3 BioCer Entwicklungs Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2020-2025)
4.5.4 BioCer Entwicklungs Emergency Hemostatic Agent Product Portfolio
4.5.5 BioCer Entwicklungs Recent Developments
4.6 Biom’Up SAS
4.6.1 Biom’Up SAS Company Information
4.6.2 Biom’Up SAS Business Overview
4.6.3 Biom’Up SAS Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Biom’Up SAS Emergency Hemostatic Agent Product Portfolio
4.6.5 Biom’Up SAS Recent Developments
4.7 C. R. Bard
4.7.1 C. R. Bard Company Information
4.7.2 C. R. Bard Business Overview
4.7.3 C. R. Bard Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2020-2025)
4.7.4 C. R. Bard Emergency Hemostatic Agent Product Portfolio
4.7.5 C. R. Bard Recent Developments
4.8 CryoLife
4.8.1 CryoLife Company Information
4.8.2 CryoLife Business Overview
4.8.3 CryoLife Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2020-2025)
4.8.4 CryoLife Emergency Hemostatic Agent Product Portfolio
4.8.5 CryoLife Recent Developments
4.9 Equimedical
4.9.1 Equimedical Company Information
4.9.2 Equimedical Business Overview
4.9.3 Equimedical Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Equimedical Emergency Hemostatic Agent Product Portfolio
4.9.5 Equimedical Recent Developments
4.10 Ethicon
4.10.1 Ethicon Company Information
4.10.2 Ethicon Business Overview
4.10.3 Ethicon Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Ethicon Emergency Hemostatic Agent Product Portfolio
4.10.5 Ethicon Recent Developments
4.11 Gelita Medical
4.11.1 Gelita Medical Company Information
4.11.2 Gelita Medical Business Overview
4.11.3 Gelita Medical Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Gelita Medical Emergency Hemostatic Agent Product Portfolio
4.11.5 Gelita Medical Recent Developments
4.12 Integra LifeSciences
4.12.1 Integra LifeSciences Company Information
4.12.2 Integra LifeSciences Business Overview
4.12.3 Integra LifeSciences Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2020-2025)
4.12.4 Integra LifeSciences Emergency Hemostatic Agent Product Portfolio
4.12.5 Integra LifeSciences Recent Developments
4.13 Marine Polymer Technologies
4.13.1 Marine Polymer Technologies Company Information
4.13.2 Marine Polymer Technologies Business Overview
4.13.3 Marine Polymer Technologies Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2020-2025)
4.13.4 Marine Polymer Technologies Emergency Hemostatic Agent Product Portfolio
4.13.5 Marine Polymer Technologies Recent Developments
4.14 The Medicines Company
4.14.1 The Medicines Company Company Information
4.14.2 The Medicines Company Business Overview
4.14.3 The Medicines Company Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2020-2025)
4.14.4 The Medicines Company Emergency Hemostatic Agent Product Portfolio
4.14.5 The Medicines Company Recent Developments
4.15 Vascular Solutions
4.15.1 Vascular Solutions Company Information
4.15.2 Vascular Solutions Business Overview
4.15.3 Vascular Solutions Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2020-2025)
4.15.4 Vascular Solutions Emergency Hemostatic Agent Product Portfolio
4.15.5 Vascular Solutions Recent Developments
4.16 Z-Medica
4.16.1 Z-Medica Company Information
4.16.2 Z-Medica Business Overview
4.16.3 Z-Medica Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2020-2025)
4.16.4 Z-Medica Emergency Hemostatic Agent Product Portfolio
4.16.5 Z-Medica Recent Developments
4.17 Pfizer
4.17.1 Pfizer Company Information
4.17.2 Pfizer Business Overview
4.17.3 Pfizer Emergency Hemostatic Agent Sales, Revenue and Gross Margin (2020-2025)
4.17.4 Pfizer Emergency Hemostatic Agent Product Portfolio
4.17.5 Pfizer Recent Developments
5 Global Emergency Hemostatic Agent Market Scenario by Region
5.1 Global Emergency Hemostatic Agent Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Emergency Hemostatic Agent Sales by Region: 2020-2031
5.2.1 Global Emergency Hemostatic Agent Sales by Region: 2020-2025
5.2.2 Global Emergency Hemostatic Agent Sales by Region: 2026-2031
5.3 Global Emergency Hemostatic Agent Revenue by Region: 2020-2031
5.3.1 Global Emergency Hemostatic Agent Revenue by Region: 2020-2025
5.3.2 Global Emergency Hemostatic Agent Revenue by Region: 2026-2031
5.4 North America Emergency Hemostatic Agent Market Facts & Figures by Country
5.4.1 North America Emergency Hemostatic Agent Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Emergency Hemostatic Agent Sales by Country (2020-2031)
5.4.3 North America Emergency Hemostatic Agent Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.5 Europe Emergency Hemostatic Agent Market Facts & Figures by Country
5.5.1 Europe Emergency Hemostatic Agent Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Emergency Hemostatic Agent Sales by Country (2020-2031)
5.5.3 Europe Emergency Hemostatic Agent Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.5.9 Nordic Countries
5.6 Asia Pacific Emergency Hemostatic Agent Market Facts & Figures by Country
5.6.1 Asia Pacific Emergency Hemostatic Agent Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Emergency Hemostatic Agent Sales by Country (2020-2031)
5.6.3 Asia Pacific Emergency Hemostatic Agent Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Emergency Hemostatic Agent Market Facts & Figures by Country
5.7.1 South America Emergency Hemostatic Agent Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Emergency Hemostatic Agent Sales by Country (2020-2031)
5.7.3 South America Emergency Hemostatic Agent Revenue by Country (2020-2031)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Emergency Hemostatic Agent Market Facts & Figures by Country
5.8.1 Middle East and Africa Emergency Hemostatic Agent Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Emergency Hemostatic Agent Sales by Country (2020-2031)
5.8.3 Middle East and Africa Emergency Hemostatic Agent Revenue by Country (2020-2031)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Emergency Hemostatic Agent Sales by Type (2020-2031)
6.1.1 Global Emergency Hemostatic Agent Sales by Type (2020-2031) & (K Units)
6.1.2 Global Emergency Hemostatic Agent Sales Market Share by Type (2020-2031)
6.2 Global Emergency Hemostatic Agent Revenue by Type (2020-2031)
6.2.1 Global Emergency Hemostatic Agent Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Emergency Hemostatic Agent Revenue Market Share by Type (2020-2031)
6.3 Global Emergency Hemostatic Agent Price by Type (2020-2031)
7 Segment by Application
7.1 Global Emergency Hemostatic Agent Sales by Application (2020-2031)
7.1.1 Global Emergency Hemostatic Agent Sales by Application (2020-2031) & (K Units)
7.1.2 Global Emergency Hemostatic Agent Sales Market Share by Application (2020-2031)
7.2 Global Emergency Hemostatic Agent Revenue by Application (2020-2031)
7.2.1 Global Emergency Hemostatic Agent Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Emergency Hemostatic Agent Revenue Market Share by Application (2020-2031)
7.3 Global Emergency Hemostatic Agent Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Emergency Hemostatic Agent Value Chain Analysis
8.1.1 Emergency Hemostatic Agent Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Emergency Hemostatic Agent Production Mode & Process
8.2 Emergency Hemostatic Agent Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Emergency Hemostatic Agent Distributors
8.2.3 Emergency Hemostatic Agent Customers
9 Global Emergency Hemostatic Agent Analyzing Market Dynamics
9.1 Emergency Hemostatic Agent Industry Trends
9.2 Emergency Hemostatic Agent Industry Drivers
9.3 Emergency Hemostatic Agent Industry Opportunities and Challenges
9.4 Emergency Hemostatic Agent Industry Restraints
10 Report Conclusion
11 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.